Formycon AG (ETR: FYB)
Germany
· Delayed Price · Currency is EUR
54.30
-2.10 (-3.72%)
Jan 21, 2025, 5:39 PM CET
Formycon AG Revenue
Formycon AG had revenue of 26.89M EUR in the half year ending June 30, 2024, with 52.42% growth. This brings the company's revenue in the last twelve months to 60.80M, down -11.42% year-over-year. In the year 2023, Formycon AG had annual revenue of 77.70M with 82.83% growth.
Revenue (ttm)
60.80M
Revenue Growth
-11.42%
P/S Ratio
14.87
Revenue / Employee
254.39K
Employees
238
Market Cap
958.77M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
Dec 31, 2019 | 33.16M | -9.84M | -22.88% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 20.96B |
Siemens Healthineers AG | 22.36B |
Bayer Aktiengesellschaft | 46.74B |
Fresenius SE & Co. KGaA | 22.81B |
Sartorius Aktiengesellschaft | 3.32B |
Fresenius Medical Care AG | 19.24B |
Carl Zeiss Meditec AG | 2.07B |
SCHOTT Pharma AG & Co. KGaA | 957.09M |
Formycon AG News
- 1 day ago - EQS-News: Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names AHZANTIVE and Baiama - Wallstreet:Online
- 6 days ago - EQS-News: Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi (ustekinumab), a biosimilar to Stelara - Wallstreet:Online
- 8 days ago - EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea/ aflibercept) in major parts of Europe and Israel - Wallstreet:Online
- 8 days ago - Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea (aflibercept) in major parts of Europe and in Israel - Wallstreet:Online
- 12 days ago - EQS-News: Formycon included in TecDAX Index of Deutsche Börse - Wallstreet:Online
- 13 days ago - EQS-News: Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi (ustekinumab), a biosimilar to Stelara - Wallstreet:Online
- 6 weeks ago - EQS-News: MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region - Wallstreet:Online
- 7 weeks ago - Formycon AG (XTER:FYB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges - GuruFocus